-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On February 22, Fosun Pharma announced that its holding subsidiary Fosun Hongchuang received approval from the State Drug Administration for the approval of the ORIN1001 tablet developed by it for clinical trials in the treatment of idiopathic pulmonary fibrosis
ORIN1001 tablet is a first-in-class small molecule drug with a new enzyme-type target, a new mechanism of action and a new chemical structure type independently developed by the group (ie the company and its holding subsidiaries/units, the same below).
As of the date of this announcement, no drug with the same target as this new drug has been launched globally
As of January 2022, the Group has invested approximately RMB 185 million (unaudited) in the current research and development of this new drug